Xencor, Inc.
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
Last updated:
Abstract:
The present invention is directed to bispecific, heterodimeric immunomodulatory antibodies.
Status:
Grant
Type:
Utility
Filling date:
8 Nov 2018
Issue date:
20 Apr 2021